PURPOSE: The vesicular acetylcholine transporter (VAChT) is a specific biomarker for imaging presynaptic cholinergic neurons. Herein, two potent and selective (11)C-labeled VAChT inhibitors were evaluated in rodents and nonhuman primates for imaging VAChT in vivo. PROCEDURES: For both (-)-[(11)C]2 and (-)-[(11)C]6, biodistribution, autoradiography, and metabolism studies were performed in male Sprague Dawley rats. Positron emission tomography (PET) brain studies with (-)-[(11)C]2 were performed in adult male cynomolgus macaques; 2 h dynamic data was acquired, and the regions of interest were drawn by co-registration of the PET images with the MRI. RESULTS: The resolved enantiomers (-)-2 and (-)-6 were very potent and selective for VAChT in vitro (K i < 5 nM for VAChT with >35-fold selectivity for VAChT vs. σ receptors); both radioligands, (-)-[(11)C]2 and (-)-[(11)C]6, demonstrated high accumulation in the VAChT-enriched striatum of rats. (-)-[(11)C]2 had a higher striatum to cerebellum ratio of 2.4-fold at 60 min; at 30 min, striatal uptake reached 0.550 ± 0.086 %ID/g. Uptake was also specific and selective; following pretreatment with (±)-2, striatal uptake of (-)-[(11)C]2 in rats at 30 min decreased by 50 %, while pretreatment with a potent sigma ligand had no significant effect on striatal uptake in rats. In addition, (-)-[(11)C]2 displayed favorable in vivo stability in rat blood and brain. PET studies of (-)-[(11)C]2 in nonhuman primates indicate that it readily crosses the blood-brain barrier (BBB) and provides clear visualization of the striatum; striatal uptake reaches the maximum at 60 min, at which time the target to nontarget ratio reached ~2-fold. CONCLUSIONS: The radioligand (-)-[(11)C]2 has high potential to be a suitable PET radioligand for imaging VAChT in the brain of living subjects.
PURPOSE: The vesicular acetylcholine transporter (VAChT) is a specific biomarker for imaging presynaptic cholinergic neurons. Herein, two potent and selective (11)C-labeled VAChT inhibitors were evaluated in rodents and nonhuman primates for imaging VAChT in vivo. PROCEDURES: For both (-)-[(11)C]2 and (-)-[(11)C]6, biodistribution, autoradiography, and metabolism studies were performed in male Sprague Dawley rats. Positron emission tomography (PET) brain studies with (-)-[(11)C]2 were performed in adult male cynomolgus macaques; 2 h dynamic data was acquired, and the regions of interest were drawn by co-registration of the PET images with the MRI. RESULTS: The resolved enantiomers (-)-2 and (-)-6 were very potent and selective for VAChT in vitro (K i < 5 nM for VAChT with >35-fold selectivity for VAChT vs. σ receptors); both radioligands, (-)-[(11)C]2 and (-)-[(11)C]6, demonstrated high accumulation in the VAChT-enriched striatum of rats. (-)-[(11)C]2 had a higher striatum to cerebellum ratio of 2.4-fold at 60 min; at 30 min, striatal uptake reached 0.550 ± 0.086 %ID/g. Uptake was also specific and selective; following pretreatment with (±)-2, striatal uptake of (-)-[(11)C]2 in rats at 30 min decreased by 50 %, while pretreatment with a potent sigma ligand had no significant effect on striatal uptake in rats. In addition, (-)-[(11)C]2 displayed favorable in vivo stability in rat blood and brain. PET studies of (-)-[(11)C]2 in nonhuman primates indicate that it readily crosses the blood-brain barrier (BBB) and provides clear visualization of the striatum; striatal uptake reaches the maximum at 60 min, at which time the target to nontarget ratio reached ~2-fold. CONCLUSIONS: The radioligand (-)-[(11)C]2 has high potential to be a suitable PET radioligand for imaging VAChT in the brain of living subjects.
Authors: R H Mach; Y Huang; N Buchheimer; R Kuhner; L Wu; T E Morton; L Wang; R L Ehrenkaufer; C A Wallen; K T Wheeler Journal: Nucl Med Biol Date: 2001-05 Impact factor: 2.408
Authors: Junfeng Li; Xiang Zhang; Zhanbin Zhang; Prashanth K Padakanti; Hongjun Jin; Jinquan Cui; Aixiao Li; Dexing Zeng; Nigam P Rath; Hubert Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu Journal: J Med Chem Date: 2013-07-18 Impact factor: 7.446
Authors: Wei Wang; Jinquan Cui; Xiaoxia Lu; Prashanth K Padakanti; Jinbin Xu; Stanley M Parsons; Robert R Luedtke; Nigam P Rath; Zhude Tu Journal: J Med Chem Date: 2011-07-20 Impact factor: 7.446
Authors: H D Gage; J C Gage; J R Tobin; A Chiari; C Tong; Z Xu; R H Mach; S M Efange; R L Ehrenkaufer; J C Eisenach Journal: Pain Date: 2001-03 Impact factor: 6.961
Authors: R B Banati; J Newcombe; R N Gunn; A Cagnin; F Turkheimer; F Heppner; G Price; F Wegner; G Giovannoni; D H Miller; G D Perkin; T Smith; A K Hewson; G Bydder; G W Kreutzberg; T Jones; M L Cuzner; R Myers Journal: Brain Date: 2000-11 Impact factor: 13.501
Authors: Hongjun Jin; Xiang Zhang; Xuyi Yue; Hui Liu; Junfeng Li; Hao Yang; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu Journal: Nucl Med Biol Date: 2015-11-07 Impact factor: 2.408
Authors: Xuyi Yue; Hongjun Jin; Hui Liu; Zonghua Luo; Xiang Zhang; Kota Kaneshige; Hubert P Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu Journal: Org Biomol Chem Date: 2017-06-21 Impact factor: 3.876
Authors: Zhude Tu; Xiang Zhang; Hongjun Jin; Xuyi Yue; Prashanth K Padakanti; Lihai Yu; Hui Liu; Hubert P Flores; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter Journal: Bioorg Med Chem Date: 2015-06-05 Impact factor: 3.641
Authors: Xuyi Yue; Zonghua Luo; Hui Liu; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu Journal: Bioorg Med Chem Lett Date: 2018-09-24 Impact factor: 2.823
Authors: Prashanth K Padakanti; Xiang Zhang; Junfeng Li; Stanley M Parsons; Joel S Perlmutter; Zhude Tu Journal: Mol Imaging Biol Date: 2014-12 Impact factor: 3.488